Vaxcyte, Inc.
NASDAQ:PCVX
116 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 10.171 | 9.196 | 1.8 | 1.405 | 1.232 | 1.037 | 0 |
| Gross Profit
| -10.171 | -9.196 | -1.8 | -1.405 | -1.232 | -1.037 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 332.341 | 169.451 | 78.411 | 73.564 | 45.607 | 30.145 | 12.785 |
| General & Administrative Expenses
| 60.7 | 39.81 | 25.259 | 16.017 | 8.546 | 5.388 | 5.048 |
| Selling & Marketing Expenses
| -10.171 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 50.529 | 39.81 | 25.259 | 16.017 | 8.546 | 5.388 | 5.048 |
| Other Expenses
| 75 | -1.931 | -1.585 | -2.478 | -0.237 | 5.178 | 0 |
| Operating Expenses
| 382.87 | 207.33 | 102.085 | 87.103 | 53.916 | 35.533 | 17.402 |
| Operating Income
| -393.041 | -232.256 | -103.67 | -89.581 | -54.153 | -35.533 | -17.833 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -9.225 | 8.771 | 3.593 | 0.364 | 3.879 | 5.22 | 0.595 |
| Income Before Tax
| -402.266 | -223.485 | -100.077 | -89.217 | -50.274 | -29.485 | -17.238 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 16.155 | 0.007 | -1.398 | 3.225 | 6.123 | 0 |
| Net Income
| -402.266 | -239.64 | -100.084 | -87.819 | -53.499 | -29.485 | -17.238 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -4.14 | -3.69 | -1.93 | -1.72 | -1.09 | -1.15 | -4.84 |
| EPS Diluted
| -4.14 | -3.69 | -1.93 | -1.72 | -1.09 | -1.15 | -4.83 |
| EBITDA
| -382.87 | -189.778 | -98.284 | -86.859 | -48.867 | -28.415 | -17.208 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |